The present study was designed to identify the endogenous RNA regulatory networks involved in hepatocellular carcinoma (HCC) by bioinformatic analysis. Both miRNA interaction network‑based correlation analysis and expression‑based Spearman correlation coefficients were utilized to identify potential mRNA‑lncRNA interactions. Then, a competitive endogenous (ce)RNA network was constructed from these interactions, and network topology and Gene Ontology enrichment analyses were conducted to mine potential functions of ceRNAs. In HCC samples, a ceRNA network was constructed. It was composed of 35,657 edges connecting 113 lncRNAs and 6,136 mRNAs which were differentially expressed in HCC and normal liver tissues. Meanwhile, a number of significantly positively correlated mRNA and lncRNA pairs in this ceRNA network were found to be consistently positively correlated in another independent dataset. To be noted, further analyses on the potential roles of ceRNAs demonstrated than various lncRNAs such as LINC00657, TUG1 and SNHG1 may play key roles in HCC by regulating protein phosphorylation or cell cycle pathways or influencing miRNAs. From the perspective that lncRNAs can function as ceRNAs, this study revealed that the interaction between lncRNAs, miRNAs and mRNAs may provide new insight for the diagnosis and treatment in the tumorigenesis of hepatocellular carcinoma.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3892/or.2019.7181 | DOI Listing |
Front Pharmacol
January 2025
Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, China.
Purpose: The present work focused on assessing whether hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and tislelizumab was safe and effective on advanced hepatocellular carcinoma (HCC) showing high tumor burden.
Methods: In the present multicenter retrospective study, treatment-naive advanced HCC patients (BCLC stage C) showing high tumor burden (maximum diameter of intrahepatic lesion beyond 7 cm) treated with lenvatinib and tislelizumab with or without HAIC were reviewed for eligibility from June 2020 to June 2023. Baseline differences between groups were mitigated by propensity score matching (PSM).
Front Immunol
January 2025
Key Laboratory of Longevity and Aging-related Diseases of Chinese Ministry of Education, Guangxi Medical University, Nanning, China.
Background: () infection is a significant risk factor for hepatocellular carcinoma (HCC), yet its underlying mechanisms remain poorly understood. This study aimed to investigate the impact of infection on the serum proteomic and metabolomic profiling of HCC patients, focusing on the potential mechanisms.
Method: A retrospective clinical analysis was conducted on 1121 HCC patients, comparing those with and without infection.
Front Immunol
January 2025
Department of Radiation Oncology, Lianyungang Second People's Hospital (Lianyungang Tumur Hospital), Lianyungang, China.
Background: Hepatocellular carcinoma (LIHC) poses a significant health challenge worldwide, primarily due to late-stage diagnosis and the limited effectiveness of current therapies. Cancer stem cells are known to play a role in tumor development, metastasis, and resistance to treatment. A thorough understanding of genes associated with stem cells is crucial for improving the diagnostic precision of LIHC and for the advancement of effective immunotherapy approaches.
View Article and Find Full Text PDFFront Immunol
January 2025
Department of Hepatobiliary Surgery, The Second Affiliated Hospital, Kunming Medical University, Kunming, China.
Purpose: This study aimed to investigate whether tumor-associated lymphatic vessel density (LVD) could predict the survival of patients with hepato-biliary-pancreatic (HBP) cancers after radical resection.
Methods: A systematic search was conducted using PubMed, Embase, and Cochrane Library from the inception to July 31, 2024 for literature that reported the role of LVD in overall survival (OS) and recurrence-free survival (RFS) of patients with HBP cancers after radical resection.
Results: Ten studies with 761 patients were included for the meta-analysis.
Front Immunol
January 2025
Tianjin Organ Transplantation Research Center, Tianjin First Central Hospital, Nankai University School of Medicine, Tianjin, China.
Organ transplantation is a life-saving intervention that enhances the quality of life for patients with end-stage organ failure. However, long-term immunosuppressive therapy is required to prevent allogeneic graft rejection, which inadvertently elevates the risk of post-transplant malignancies, especially for liver transplant recipients with a prior history of liver cancer. In response, the emerging field of transplant oncology integrates principles from oncology and immunology to improve outcomes for patients at high risk of tumor occurrence or recurrence following transplantation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!